Human Gene Therapy · 2018 · 39 citations · 44 references
Life SciencesGeneticsMolecular BiologyGene ExpressionGene TherapyTranscriptomicsGene Expression In NeuronsNeurological Gene TherapyOcular Gene TherapyPromoter DesignLeber Hereditary Optic NeuropathyMinimal Promoter ArchitectureOptogenetic Gene TherapyOptogenetic TherapyPromoter Element DiscoveryRetinal Ganglion Cell DisordersRetinal Ganglion Cell Transcriptional RegulationRetinal Optogenetics
Retinal gene therapy is leading the neurological gene therapy field, with 32 ongoing clinical trials of recombinant adeno-associated virus (rAAV)-based therapies. Importantly, over 50% of those trials are using restricted promoters from human genes. Promoters that restrict expression have demonstrated increased efficacy and can limit the therapeutic to the target cells thereby reducing unwanted off-target effects. Retinal ganglion cells are a critical target in ocular gene therapy; they are involved in common diseases such as glaucoma, rare diseases such as Leber's hereditary optic neuropathy, and in revolutionary optogenetic treatments. Here, we used computational biology and mined the human genome for the best genes from which to develop a novel minimal promoter element(s) designed for expression in restricted cell types (MiniPromoter) to improve the safety and efficacy of retinal ganglion cell gene therapy. Gene selection included the use of the first available droplet-based single-cell RNA sequencing (Drop-seq) dataset, and promoter design was bioinformatically driven and informed by a wide range of genomics datasets. We tested seven promoter designs from four genes in rAAV for specificity and quantified expression strength in retinal ganglion cells in mouse, and then the single best in nonhuman primate retina. Thus, we developed a new human-DNA MiniPromoter, Ple345 (NEFL), which in combination with intravitreal delivery in rAAV9 showed specific and robust expression in the retinal ganglion cells of the nonhuman-primate rhesus macaque retina. In mouse, we also developed MiniPromoters expressing in retinal ganglion cells, the hippocampus of the brain, a pan neuronal pattern in the brain, and peripheral nerves. As single-cell transcriptomics such as Drop-seq become available for other cell types, many new opportunities for additional novel restricted MiniPromoters will present.
44
An integrated encyclopedia of DNA elements in the human genome
The Human Genome Browser at UCSC
W. James Kent, Charles W. Sugnet, Terrence S. Furey et al. · Genome Research · 2002 · 10.9K citations · Full text
Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets
Evan Z. Macosko, Anindita Basu, Rahul Satija et al. · Cell · 2015 · 7.8K citations · Full text
An atlas of active enhancers across human cell types and tissues
Robin Andersson, Claudia Gebhard, Irene Miguel-Escalada et al. · Nature · 2014 · 2.8K citations · Full text
Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Jerry R. Mendell, Samiah Al-Zaidy, Richard Shell et al. · New England Journal of Medicine · 2017 · 2.3K citations · Full text